As Sandoz gears up to launch of one of the most anticipated biosimilars of the year, the company could face near-term ...

Today, Benzinga 's options scanner spotted 28 uncommon options trades for Amgen. This isn't normal. The overall sentiment of ...

Situated in the core of the NC Research Triangle, the site at Camp Helix Innovation Park is a substantial regional investment ...

Amgen Inc . (NASDAQ:AMGN), a leading biopharmaceutical company with a market capitalization of $149 billion, is navigating a ...

This December, Amgen received a second state incentive to expand its Holly Springs operations by adding another drug ...

The U.S. Food and Drug Administration approved Amgen's combination therapy on Thursday to treat colorectal cancer in patients ...

Amgen executives and employees, local and state elected dignitaries, and an assortment of other local economic development ...

Amgen (Nasdaq: AMGN) has completed construction of a $550 million drug manufacturing facility in the Wake County town. Meanwhile, the company on Friday kicked off construction on a second ...

Amgen’s Lumakras and AstraZeneca’s Calquence are both in line to expand their respective oncology reaches with new FDA ...

The U.S. Food and Drug Administration (FDA) gave Amgen (NASDAQ:AMGN) approval to use its KRASG12C inhibitor Lumakras with Vectibix for treating advanced colorectal cancer. Warning! GuruFocus has ...

However, the spotlight is on Amgen's obesity drug candidate, MariTide. This product is generating significant buzz in the investment community due to its potential to become a major revenue driver.